Richard Morris - Cardax Insider

CDXI -- USA Stock  

USD 0.21  0.01  5.00%

  Executive
Mr. Richard M. Morris is Secretary of the Cardax, Inc. Mr. Morris has served as Assistant Secretary of Pharma since May 2013 and Assistant Secretary of Holdings since July 2013. Mr. Morris is a Partner at Herrick, Feinstein LLP, our legal counsel . As a partner of Herrick, Mr. Morris represents a variety of clients, primarily in corporate matters. Prior to becoming a lawyer, Mr. Morris was an auditor with the Commodities Exchange in New York and later focused on operations and financial management at Kidder Peabody. He also was the U.S. Audit Manager for the financial division for a diversified Australian company
Age: 54  Executive Since 2014      
808-457-1400  http://www.cardaxpharma.com
Morris has a B.S. in Accounting from New York University and a J.D. from Fordham University School of Law, with bar admissions in New York and Connecticut.

Management Efficiency

The company has return on total asset (ROA) of (111.6) % which means that it has lost $111.6 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (12.0) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Paul FosterXencor
2015
Anne TrotouxCoppermannAlder Biopharmaceuticals
2013
Philippe MattiaAlder Biopharmaceuticals
2013
Jim GlasheenRevance Therapeutics
N/A
Adam WaldmanTG Therapeutics
2018
Cyril AlloucheRevance Therapeutics
2018
Edgardo BaracchiniXencor
2010
Albert RobichaudSage Therapeutics
2011
Eric CarterAlder Biopharmaceuticals
2018
Jonathan TunnicliffeRevance Therapeutics
2011
Timothy WhitakerAlder Biopharmaceuticals
2016
Michael CloonanSage Therapeutics
2017
Phyllis GardnerRevance Therapeutics
2006
Ronald EastmanRevance Therapeutics
N/A
Elisabeth SandovalAlder Biopharmaceuticals
2018
Mark LittonAlder Biopharmaceuticals
N/A
Olivier LambertAlder Biopharmaceuticals
2013
Joel DesmarisAlder Biopharmaceuticals
2013
Bruno PavlovskyAlder Biopharmaceuticals
2013
Thomas AndersonSage Therapeutics
2014
Xavier GallotLavalleeAlder Biopharmaceuticals
2013

Entity Summary

Cardax, Inc., a life sciences company, develops and commercializes consumer health and pharmaceutical products for anti-inflammatory benefits primarily in Hawaii. Cardax, Inc. was incorporated in 2012 and is based in Honolulu, Hawaii. Cardax operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 11 people.Cardax (CDXI) is traded on OTC Market in USA. It is located in 2800 Woodlawn Drive and employs 11 people.

Cardax Leadership Team

George Bickerstaff, Independent Director
Nicholas Mitsakos, Executive Chairman
Richard Morris, Secretary
Tamar Howson, Independent Director
Gilbert Shin, Vice President - Retail Sales and Marketing
Elona Kogan, Independent Director
Frank Herringer, Director
Makarand Jawadekar, Independent Director
Terence Kelly, Independent Director
David Watumull, VP of Operations, Assistant Treasurer and Assistant Secretary
Michele Galen, Independent Director
John Russell, CFO, Treasurer

Stock Performance Indicators

Did you try this?

Run Cryptocurrency Arbitrage Now
   

Cryptocurrency Arbitrage

Find pairs of digital assets on multiple exchanges that are traded at a risk free arbitrage
All  Next Launch Cryptocurrency Arbitrage

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Cardax and Regeneron Pharmaceuticals. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.